Eryseng Parvo

Country: European Union

Language: Danish

Source: EMA (European Medicines Agency)

Buy It Now

Patient Information leaflet Patient Information leaflet (PIL)
13-05-2019
Summary of Product characteristics Summary of Product characteristics (SPC)
13-05-2019
Public Assessment Report Public Assessment Report (PAR)
03-10-2014

Active ingredient:

porcint parvovirus, stamme NADL-2 og Erysipelothrix rhusiopathiae, stamme R32E11 (inaktiveret)

Available from:

Laboratorios Hipra, S.A.

ATC code:

QI09AL01

INN (International Name):

Porcine parvovirus and Erysipelothrix rhusiopathiae

Therapeutic group:

svin

Therapeutic area:

Immunologicals for suidae, Inactivated viral and inactivated bacterial vaccines

Therapeutic indications:

Til aktiv immunisering af kvindesvin til beskyttelse af afkom mod transplacental infektion forårsaget af svineparvovirus. Til aktiv immunisering af han- og kvindesvin til nedsættelse af kliniske tegn (hudlæsioner og feber) af svin erysipelas forårsaget af Erysipelothrix rhusiopathiae, serotype 1 og serotype 2.

Product summary:

Revision: 5

Authorization status:

autoriseret

Authorization date:

2014-07-08

Patient Information leaflet

                                14
B. INDLÆGSSEDDEL
15
INDLÆGSSEDDEL:
ERYSENG PARVO INJEKTIONSVÆSKE, SUSPENSION TIL GRISE
1.
NAVN OG ADRESSE PÅ INDEHAVEREN AF MARKEDSFØRINGSTILLADELSEN
SAMT PÅ DEN INDEHAVER AF VIRKSOMHEDSGODKENDELSE, SOM ER
ANSVARLIG FOR BATCHFRIGIVELSE, HVIS FORSKELLIG HERFRA
Indehaver af markedsføringstilladelsen og fremstiller ansvarlig for
batchfrigivelse:
LABORATORIOS HIPRA, S.A.
Avda. la Selva, 135
17170 Amer (Girona)
SPAIN
2.
VETERINÆRLÆGEMIDLETS NAVN
ERYSENG PARVO injektionsvæske, suspension til grise
3.
ANGIVELSE AF DE(T) AKTIVE STOF(FER) OG ANDRE INDHOLDSSTOFFER
Hver dosis på 2 ml indeholder:
Inaktiveret Porcin Parvovirus, stamme NADL-2
..................................................... RP > 1,15.
Inaktiveret
_Erysipelothrix rhusiopathiae_
, stamme R32E11 .......... ELISA > 3,34 log
2
IE
50 %
**
* RP, Relativ Potens (ELISA)
** hæmning ELISA - 50 %
Aluminiumhydroxid
.............................................................................................
5,29 mg (aluminium)
DEAE-dextran
Ginseng
Hvidlig suspension til injektion.
4.
INDIKATIONER
Til aktiv immunisering af søer til beskyttelse af afkom mod
transplacental infektion forårsaget af
porcin parvovirus.
Til aktiv immunisering af han- og hungrise for at reducere kliniske
tegn (hudlæsioner og feber) på
svine-erysipelas forårsaget af
_Erysipelothrix rhusiopathiae_
, serotype 1 og serotype 2.
Indtræden af immunitet:
Porcin parvovirus: Fra begyndelsen af drægtighedsperioden.
E. rhusiopathiae: Tre uger efter gennemførelse af
basisvaccinationsplanen.
Varighed af immunitet:
Porcin parvovirus: Vaccination giver føtal beskyttelse i hele
drægtighedsperioden. Revaccination bør
udføres før hver drægtighed, se afsnit ”Dosering for hver
dyreart, anvendelsesmåde og
indgivelsesvej(e)”.
E. rhusiopathiae: Vaccination beskytter mod svine-erysipelas indtil
tidspunktet for den anbefalede
revaccination (cirka seks måneder efter basisvaccinationsplanen), se
afsnit ”Dosering for hver
dyreart, anvendelsesmåde og indgivelsesvej(e)”.
16
5.
KONTRAI
                                
                                Read the complete document

Summary of Product characteristics

                                1
BILAG I
PRODUKTRESUME
2
1.
VETERINÆRLÆGEMIDLETS NAVN
ERYSENG PARVO injektionsvæske, suspension til grise
2.
KVALITATIV OG KVANTITATIV SAMMENSÆTNING
Hver dosis på 2 ml indeholder:
AKTIVE STOFFER:
Inaktiveret porcin parvovirus, stamme NADL-2
.................................................... RP > 1,15 *
Inaktiveret
_Erysipelothrix rhusiopathiae_
, stamme R32E11 .......... ELISA > 3,34 log
2
IE
50 %
**
* RP, relativ potens (ELISA)
** IE
50 %
hæmning ELISA - 50 %
ADJUVANSER:
Aluminiumhydroxid …………………….
............................................... 5,29 mg (aluminium)
DEAE-dextran
Ginseng.
Alle hjælpestoffer er anført under pkt. 6.1
3.
LÆGEMIDDELFORM
Injektionsvæske, suspension
Hvidlig suspension
4.
KLINISKE OPLYSNINGER
4.1
DYREARTER, SOM LÆGEMIDLET ER BEREGNET TIL
Svin
4.2
TERAPEUTISKE INDIKATIONER MED ANGIVELSE AF DYREARTER, SOM LÆGEMIDLET
ER BEREGNET TIL
Til aktiv immunisering af søer til beskyttelse af afkom mod
transplacental infektion forårsaget af
porcin parvovirus.
Til aktiv immunisering af han- og hungrise for at reducere kliniske
tegn (hudlæsioner og feber) på
svine-erysipelas (rødsyge) forårsaget af
_Erysipelothrix rhusiopathiae_
, serotype 1 og serotype 2.
Indtræden af immunitet:
Porcin parvovirus: Fra begyndelsen af drægtighedsperioden.
_E. rhusiopathiae_
: Tre uger efter gennemførelse af basisvaccinationsplanen.
Varighed af immunitet:
Porcin parvovirus: Vaccination giver føtal beskyttelse i hele
drægtighedsperioden. Revaccination bør
udføres før hver drægtighed, se afsnit 4.9.
_E. rhusiopathiae_
: Vaccination beskytter mod svine-erysipelas indtil tidspunktet for
den anbefalede
revaccination (cirka seks måneder efter basisvaccinationsplanen), se
afsnit 4.9.
4.3
KONTRAINDIKATIONER
Bør ikke anvendes i tilfælde af overfølsomhed over for de aktive
stoffer, adjuvanserne eller et eller
flere af hjælpestofferne.
3
4.4
SÆRLIGE ADVARSLER FOR HVER ENKELT DYREART, SOM LÆGEMIDLET ER
BEREGNET TIL
Kun raske dyr må vaccineres.
4.5
SÆRLIGE FORSIGTIGHEDSREGLER VEDR
                                
                                Read the complete document

Similar products

Active ingredient porcint parvovirus, stamme NADL-2 og Erysipelothrix rhusiopathiae, stamme R32E11 (inaktiveret)

porcint parvovirus, stamme NADL-2 og Erysipelothrix rhusiopathiae, stamme R32E11 (inaktiveret)

ATC code QI09AL01

QI09AL01

Marketed by Laboratorios Hipra, S.A.

Laboratorios Hipra, S.A.

INN (International Name) Porcine parvovirus and Erysipelothrix rhusiopathiae

Porcine parvovirus and Erysipelothrix rhusiopathiae

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 13-05-2019
Summary of Product characteristics Summary of Product characteristics Bulgarian 13-05-2019
Public Assessment Report Public Assessment Report Bulgarian 03-10-2014
Patient Information leaflet Patient Information leaflet Spanish 13-05-2019
Summary of Product characteristics Summary of Product characteristics Spanish 13-05-2019
Public Assessment Report Public Assessment Report Spanish 03-10-2014
Patient Information leaflet Patient Information leaflet Czech 13-05-2019
Summary of Product characteristics Summary of Product characteristics Czech 13-05-2019
Public Assessment Report Public Assessment Report Czech 03-10-2014
Patient Information leaflet Patient Information leaflet German 13-05-2019
Summary of Product characteristics Summary of Product characteristics German 13-05-2019
Public Assessment Report Public Assessment Report German 03-10-2014
Patient Information leaflet Patient Information leaflet Estonian 13-05-2019
Summary of Product characteristics Summary of Product characteristics Estonian 13-05-2019
Public Assessment Report Public Assessment Report Estonian 03-10-2014
Patient Information leaflet Patient Information leaflet Greek 13-05-2019
Summary of Product characteristics Summary of Product characteristics Greek 13-05-2019
Public Assessment Report Public Assessment Report Greek 03-10-2014
Patient Information leaflet Patient Information leaflet English 13-05-2019
Summary of Product characteristics Summary of Product characteristics English 13-05-2019
Public Assessment Report Public Assessment Report English 03-10-2014
Patient Information leaflet Patient Information leaflet French 13-05-2019
Summary of Product characteristics Summary of Product characteristics French 13-05-2019
Public Assessment Report Public Assessment Report French 03-10-2014
Patient Information leaflet Patient Information leaflet Italian 13-05-2019
Summary of Product characteristics Summary of Product characteristics Italian 13-05-2019
Public Assessment Report Public Assessment Report Italian 03-10-2014
Patient Information leaflet Patient Information leaflet Latvian 13-05-2019
Summary of Product characteristics Summary of Product characteristics Latvian 13-05-2019
Public Assessment Report Public Assessment Report Latvian 03-10-2014
Patient Information leaflet Patient Information leaflet Lithuanian 13-05-2019
Summary of Product characteristics Summary of Product characteristics Lithuanian 13-05-2019
Public Assessment Report Public Assessment Report Lithuanian 03-10-2014
Patient Information leaflet Patient Information leaflet Hungarian 13-05-2019
Summary of Product characteristics Summary of Product characteristics Hungarian 13-05-2019
Public Assessment Report Public Assessment Report Hungarian 03-10-2014
Patient Information leaflet Patient Information leaflet Maltese 13-05-2019
Summary of Product characteristics Summary of Product characteristics Maltese 13-05-2019
Public Assessment Report Public Assessment Report Maltese 03-10-2014
Patient Information leaflet Patient Information leaflet Dutch 13-05-2019
Summary of Product characteristics Summary of Product characteristics Dutch 13-05-2019
Public Assessment Report Public Assessment Report Dutch 03-10-2014
Patient Information leaflet Patient Information leaflet Polish 13-05-2019
Summary of Product characteristics Summary of Product characteristics Polish 13-05-2019
Public Assessment Report Public Assessment Report Polish 03-10-2014
Patient Information leaflet Patient Information leaflet Portuguese 13-05-2019
Summary of Product characteristics Summary of Product characteristics Portuguese 13-05-2019
Public Assessment Report Public Assessment Report Portuguese 03-10-2014
Patient Information leaflet Patient Information leaflet Romanian 13-05-2019
Summary of Product characteristics Summary of Product characteristics Romanian 13-05-2019
Public Assessment Report Public Assessment Report Romanian 03-10-2014
Patient Information leaflet Patient Information leaflet Slovak 13-05-2019
Summary of Product characteristics Summary of Product characteristics Slovak 13-05-2019
Public Assessment Report Public Assessment Report Slovak 03-10-2014
Patient Information leaflet Patient Information leaflet Slovenian 13-05-2019
Summary of Product characteristics Summary of Product characteristics Slovenian 13-05-2019
Public Assessment Report Public Assessment Report Slovenian 03-10-2014
Patient Information leaflet Patient Information leaflet Finnish 13-05-2019
Summary of Product characteristics Summary of Product characteristics Finnish 13-05-2019
Public Assessment Report Public Assessment Report Finnish 03-10-2014
Patient Information leaflet Patient Information leaflet Swedish 13-05-2019
Summary of Product characteristics Summary of Product characteristics Swedish 13-05-2019
Public Assessment Report Public Assessment Report Swedish 03-10-2014
Patient Information leaflet Patient Information leaflet Norwegian 13-05-2019
Summary of Product characteristics Summary of Product characteristics Norwegian 13-05-2019
Patient Information leaflet Patient Information leaflet Icelandic 13-05-2019
Summary of Product characteristics Summary of Product characteristics Icelandic 13-05-2019
Patient Information leaflet Patient Information leaflet Croatian 13-05-2019
Summary of Product characteristics Summary of Product characteristics Croatian 13-05-2019
Public Assessment Report Public Assessment Report Croatian 03-10-2014

Search alerts related to this product

Alerts Eryseng Parvo porcint parvovirus, stamme NADL-2 Porcine and Erysipelothrix rhusiopathiae

Eryseng Parvo porcint parvovirus, stamme NADL-2 Porcine and Erysipelothrix rhusiopathiae

View documents history

Documents history Documents history

Eryseng Parvo